Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
UK medtech company Creavo Medical Technologies is trying to bring its magnetocardiography (MCG) technology to emergency departments worldwide to help physicians accurately rule out heart disease. Distinguishing between ischemic heart disease and non-cardiac chest pain remains a challenge in emergency departments. Currently, all patients presenting with chest pain are assessed with electrocardiography and blood tests to rule out heart disease, but almost three-quarters of patients with chest pain do not have a cardiac-related condition.
In this edition of the Device Week podcast, Medtech Insight’s Reed Miller talks about the latest good news for LivaNova and Catherine Longworth provides an update on Creavo Medical, a UK-based company using an old technology for a new kind of cardiac test that could save hospitals money.
Swiss-based Vivior AG has developed a wearable Visual Behavior Monitor (VBM) designed to help surgical ophthalmologists determine the best treatment options for patients. The company's initial target is the $2.15bn global refractive and cataract surgery market.
Start-Up Spotlight: Embolx Believes Balloon Microcatheter Occlusion Will Be A 'Breakthrough' For BPH, Cancer
Embolx is having a big year. US FDA cleared its Sniper balloon occlusion microcatheter for pressure-directed arterial embolization a few months after the UK's NICE issued recommendations supporting prostate artery embolization for lower urinary tract symptoms caused by benign prostatic hyperplasia. Now the company is focused on improving market penetration by investing in physician-education and supporting research on new applications of targeted embolization, hoping to attract commercial partners or a possible acquirer.
Infused with a fresh round of financing led by Boston Scientific, RenovoRx has begun a multicenter Phase 3 study of its dual-balloon infusion catheter to treat pancreatic cancer. The study will randomize therapy to either the RenovoCath System with the drug gemcitabine or to systemic chemotherapy with gemcitabine and Celgene’s drug nab-paclitaxel delivered intravenously. The goal is to extend the current standard-of-care survival period from about one year to over two years.
A UK drug-delivery firm is bringing its antimicrobial material to the global wound-care market. Pertinax Pharma, a Bristol University spin-out, is the developer of a slow-release technology that provides controlled and sustained delivery of the antiseptic chlorhexidine.
Start-Up Spotlight: Payers, Pharma Clients Bank On Prognos' Artificial Intelligence To Predict Disease
New York-based health IT company Prognos recently secured $20.5m in Series C financing to build out its artificial intelligence capabilities, which it has applied to a giant diagnostic laboratory registry containing data from some 180 million patients. Given the shift to value-based health care and the high costs of treating chronic diseases, insurers might use information from this registry to predict the likelihood of disease and reach out to members to help head off illnesses. Pharma clients, in turn, can use the data to target physicians to help them deliver effective treatments.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.